<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2018.73022</article-id><article-id pub-id-type="publisher-id">HJO-27034</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20180300000_65375905.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  糖化血红蛋白对577 nm阈下微脉冲激光治疗糖尿病黄斑水肿的影响
  Effect of Glycosylated Hemoglobin on 577 nm Subthreshold Micro Pulse Laser in Treatment of Diabetic Macular Edema
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>奕霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>练</surname><given-names>海东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>剑锋</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>娜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>石河子大学医学院第一附属医院眼科，新疆 石河子</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>08</month><year>2018</year></pub-date><volume>07</volume><issue>03</issue><fpage>143</fpage><lpage>148</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨糖化血红蛋白对577 nm阈下微脉冲激光治疗糖尿病黄斑水肿的影响。方法：选择2013年5月~2017年9月在石河子大学医学院一附院眼科经散瞳眼底检查、眼底荧光素血管造影(Fluorescein Fundus Angiography, FFA)及光学相干断层扫描(Optical Coherence Tomography, OCT)检查确诊的DME患者62例(68眼)作为研究对象，激光术前三天糖化血红蛋白(HbA1c)的检测，根据HbA1c水平将糖尿病黄斑水肿分为低HbA1c组(HbA1c ≤ 7.0%) 32例(35眼)和高HbA1c组(HbA1c &gt; 7.0%) 30例(33眼)，两组患者黄斑区均进行577 nm阈下微脉冲激光治疗两次，激光治疗前及治疗后1周，1月，2月，3月，自身对比及组间对比分析两组患者治疗前后最佳矫正视力(Best Corrected Visual Acuity, BCVA)、黄斑中心厚度(Central Macular Thickness, CMT)、黄斑总容积、黄斑10˚范围内视网膜光敏感度的变化。结果：低HbA1c组及高HbA1c组DME经577 nm阈下微脉冲激光治疗一月后黄斑容积，黄斑中心厚度降低，黄斑中心视网膜光敏感度，最佳矫正视力提高，较术前均有显著差异(P &lt; 0.05)。术后两月，三月两组CMT、黄斑总容积部分增加，高HbA1c组增加更明显，较低HbA1c组有统计学意义。术后三月组间比较BCVA、黄斑中心视敏感度均有统计学意义(P &lt; 0.05)。结论：微脉冲激光治疗糖尿病DME疗效肯定，糖化血红蛋白的良好控制有利于577 nm阈下微脉冲激光治疗效果的巩固。
    Objective: To explore the clinical value of glycosylated hemoglobin after 577 nm yellow micropulse laser in Diabetic Macular Edema. Methods: For examination of fundus, fluorescence fundus angiography and optical coherence tomography (OCT) examination of 62 patients (68 eyes) with DME were enrolled in this study from May 2013 to Sep 2017 in ophthalmology department of our hospital. All patients were divided into high HbA1c group (HbA1c &gt; 7.0%) (30 patients with 33 eyes) and low HbA1c group (HbA1c ≤ 7.0%) (32patients with 35eyes) by detection of HbA1c values three days before the twice laser therapy. The total macular volume, central retinal thickness, best corrected visual acuity and central 10˚ visual acuity of the macula were observed before and 1 week, 1 mon, 2 mon, and 3 mon after 577 nm yellow micropulse laser therapy in two groups. Result: The total volume of macular retinal and the central retinal thickness of macular area in two groups (low HbA1c group and high HbA1c group) with DME decreased significantly after a month by 577 nm yellow micro pulse laser treatment. The macular central retinal photosensitivity and the best corrected visual acuity in two groups improved significantly after a month by laser treatment. These were significantly different from those before laser treatment (P &lt; 0.05). In two and three months, the total volume of macular retinal and the central retinal thickness of macular area in two groups increased again partially and the increase was more obvious in the high HbA1c group and statistically significant with the low HbA1c group. The best corrected visual acuity and central visual acuity of macula were statistically significant between the two groups at 3 months after laser treatment (P &lt; 0.05). Conclusion: The effect of 577 nm yellow micro pulse laser for DME is positive, and the good control of glycosylated hemoglobin is conducive to the continuation of the therapeutic effect of micro-pulse laser. 
  
 
</p></abstract><kwd-group><kwd>糖尿病黄斑水肿，糖化血红蛋白，微脉冲激光, Diabetic Macular Edema</kwd><kwd> Glycosylated Hemoglobin</kwd><kwd> Micropulse Photocoagulation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>糖化血红蛋白对577 nm阈下微脉冲激光 治疗糖尿病黄斑水肿的影响<sup> </sup></title><p>张奕霞，练海东，丁剑锋，李娜</p><p>石河子大学医学院第一附属医院眼科，新疆 石河子</p><p><img src="//html.hanspub.org/file/5-2230206x1_hanspub.png" /></p><p>收稿日期：2018年9月4日；录用日期：2018年9月22日；发布日期：2018年9月29日</p><disp-formula id="hanspub.27034-formula49"><graphic xlink:href="//html.hanspub.org/file/5-2230206x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨糖化血红蛋白对577 nm阈下微脉冲激光治疗糖尿病黄斑水肿的影响。方法：选择2013年5月~2017年9月在石河子大学医学院一附院眼科经散瞳眼底检查、眼底荧光素血管造影(Fluorescein Fundus Angiography, FFA)及光学相干断层扫描(Optical Coherence Tomography, OCT)检查确诊的DME患者62例(68眼)作为研究对象，激光术前三天糖化血红蛋白(HbA1c)的检测，根据HbA1c水平将糖尿病黄斑水肿分为低HbA1c组(HbA1c ≤ 7.0%) 32例(35眼)和高HbA1c组(HbA1c &gt; 7.0%) 30例(33眼)，两组患者黄斑区均进行577 nm阈下微脉冲激光治疗两次，激光治疗前及治疗后1周，1月，2月，3月，自身对比及组间对比分析两组患者治疗前后最佳矫正视力(Best Corrected Visual Acuity, BCVA)、黄斑中心厚度(Central Macular Thickness, CMT)、黄斑总容积、黄斑10˚范围内视网膜光敏感度的变化。结果：低HbA1c组及高HbA1c组DME经577 nm阈下微脉冲激光治疗一月后黄斑容积，黄斑中心厚度降低，黄斑中心视网膜光敏感度，最佳矫正视力提高，较术前均有显著差异(P &lt; 0.05)。术后两月，三月两组CMT、黄斑总容积部分增加，高HbA1c组增加更明显，较低HbA1c组有统计学意义。术后三月组间比较BCVA、黄斑中心视敏感度均有统计学意义(P &lt; 0.05)。结论：微脉冲激光治疗糖尿病DME疗效肯定，糖化血红蛋白的良好控制有利于577 nm阈下微脉冲激光治疗效果的巩固。</p><p>关键词 :糖尿病黄斑水肿，糖化血红蛋白，微脉冲激光</p><disp-formula id="hanspub.27034-formula50"><graphic xlink:href="//html.hanspub.org/file/5-2230206x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-2230206x7_hanspub.png" /> <img src="//html.hanspub.org/file/5-2230206x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>黄斑水肿是糖尿病患者视力低下及视力丧失的最主要因素，糖尿病黄斑水肿的发生率随着糖尿病患者病程及病变的程度增加而增加 [<xref ref-type="bibr" rid="hanspub.27034-ref1">1</xref>] 。黄斑的格栅样光凝是治疗黄斑水肿的经典方法，却无法完全避免逐渐扩大的激光斑、黄斑区的萎缩，光斑损伤甚至诱发黄斑区新生血管生成 [<xref ref-type="bibr" rid="hanspub.27034-ref2">2</xref>] 。黄斑区解剖结构及对精细视觉的重要性决定了黄斑水肿的治疗不能有瘢痕的增生和色素的紊乱。近年来抗VEGF药物玻璃体腔注射对黄斑水肿有肯定的疗效 [<xref ref-type="bibr" rid="hanspub.27034-ref3">3</xref>] ，但是需要反复注射，增加眼内感染的风险，且价格昂贵，患者需要承受巨大的经济负担。阈下微脉冲的激光治疗已经证实在曝光时间不超过100 us的情况下，只有RPE细胞起作用，不产生任何痕迹，且可以重复治疗 [<xref ref-type="bibr" rid="hanspub.27034-ref4">4</xref>] 。但是微脉冲激光治疗后黄斑区水肿可以再次出现，导致视力的下降，如何才能更好的巩固微脉冲激光治疗的效果，本研究对比不同糖化血红蛋白的条件下微脉冲激光的治疗，现报告如下。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取2013年5月~2017年9月就诊石河子大学医学院第一附属医院眼科，经散瞳眼底检查、眼底荧光血管造影(Fluorescence Fundus Angiography, FFA)及光学相干断层扫描(Optical Coherence Tomography, OCT)检查确诊的DME患者62例(68眼)。纳入标准：确诊II型糖尿病患者、空腹血糖 ≤ 8.0 mmol/L，后续三个月不改变降糖方式及饮食方式。年龄50~70岁，男女不限，糖尿病病程7~21年，最佳矫正视力 ≥ 0.01，OCT显示黄斑区弥漫性水肿或囊样水肿。排除标准：严重全身疾病、视神经及青光眼等相关疾病，眼表急慢性感染、屈光间质混浊影响眼底观察及激光治疗者、OCT黄斑区牵拉水肿，任何相关激光、玻璃体药物注射及其他经眼科手术治疗的DME。所有患者知情同意，且经过笔者院伦理委员会批准。</p></sec><sec id="s4_2"><title>2.2. 治疗方法</title><sec id="s4_2_1"><title>2.2.1. 治疗前后检查</title><p>所有患者术前术后均行最佳矫正视力、FFA、OCT及黄斑10˚视野检查。最佳矫正视力采用Topcon全自动验光仪和标准视力表进行，法国光太激光荧光眼底血管造影仪行FFA检查；Topcon OCT仪测量黄斑中心凹处厚度(CMT)、黄斑容积。德国蔡司Humphrey视野计测量黄斑10˚范围视网膜光敏感度值，取瞳孔直径为3 mm，刺激光标为III级白色光标，背景31.5ASB，记录黄斑10˚光敏感度值。</p></sec><sec id="s4_2_2"><title>2.2.2. 激光治疗</title><p>法国光太(Supra 577)黄色激光阈下微脉冲治疗程序对DME进行治疗。参数设置：工作时间0.17 ms，间歇时间1 ms，工作负载率15%，光斑直径100 μm，光斑间距一个光斑直径。能量100~200 mw，距黄斑中心凹500 μm外上下血管弓内治疗范围。所有患者黄斑区577 nm阈下微脉冲激光治疗三日后再重复一次。治疗前及治疗后1周、1个月、2月、3个月，进行最佳矫正视力、OCT及微视野检查。</p></sec></sec><sec id="s4_3"><title>2.3. 分组统计</title><p>根据激光术前HbA1c ≤ 7.0%分为低HbA1c组34例(35眼)，HbA1c &gt; 7.0%为高HbA1c组28例(33眼)，采用SPSS17统计学软件行分析，所有数据以 x &#175; &#177; s 表示。治疗前后最佳矫正视力、CMT、黄斑容积及光敏感度值比较采用重复数据测量，检验水准α = 0.05。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>1) 激光治疗前两组患者的病程、最佳矫正视力、黄斑中心厚度、黄斑容积、黄斑中心视敏度均符合正态分布，方差齐平，不具有统计学差异。</p><p>2) 577 nm阈下微脉冲激光治疗两组DME患者术后一周，两组的BCVA较治疗前均没有明显改善，治疗后一月低HbA1C组视力提高，较术前比较有统计差异，高HbA1C组术后一月视力提高，较术前无明显差异。随者时间延长，两组BCVA较术后一月有所下降。见表1。</p><p>3) 对于黄斑中心厚度的影响如表2所见，两组患者激光治疗后CMT于术后一周以后开始降低，术后一月时降至最低，较术前均有明显差异，尤其是低HbA1C组较高HbA1C组CMT降低更多，有显著统计学差异。低HbA1C组激光治疗后两月，三月CMT较术后一月略有增加，但相较术前仍有显著差异，高HbA1C组激光治疗后两月，CMT较术后一月略有增加，较术前有显著差异，三月时CMT增加较术前没有差异，较低HbA1C组三月时有统计学差异。提示低HbA1C组激光治疗后CMT降低稳定更长时间。</p><p>4) 黄斑总容积反应黄斑区综合水肿情况，两组DME患者激光治疗后一月、两月黄斑容积均明显减少，较术前有统计学差异，术后三月，两组黄斑容积较一月时有所增加，但高HbA1C组增加多于低HbA1C组，有统计学差异。提示低HbA1C组较高HbA1C组激光治疗后黄斑总容积下降维持更长时间。见表3。</p><p>5) 黄斑中心视敏度结果见表4。两组DME患者激光治疗后黄斑中心视敏度提高，低HbA1C组一月时较术前有显著差异，高HbA1C组较术前无显著差异，但三月时低HbA1C较高HbA1C组有显著差异。</p></sec><sec id="s6"><title>4. 讨论</title><p>糖尿病黄斑水肿目前多认为在血糖持续升高时，可能引起视网膜缺氧，从而产生多种炎症因子，该种类炎症因子及糖基化终产物的长期慢性相互作用，进一步导致血视网膜屏障破坏以及血管通透性的改</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The influence of different HbA1c and time on BCV</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后一周</th><th align="center" valign="middle" >术后一月</th><th align="center" valign="middle" >术后两月</th><th align="center" valign="middle" >术后三月</th><th align="center" valign="middle" >F<sub>HbA1C</sub></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >低HbA1C组(n = 35)</td><td align="center" valign="middle" >0.14 &#177; 0.10</td><td align="center" valign="middle" >0.15 &#177; 0.10</td><td align="center" valign="middle" >0.22 &#177; 0.11<sup>ab </sup></td><td align="center" valign="middle" >0.21 &#177; 0.10</td><td align="center" valign="middle" >0.20 &#177; 0.11</td><td align="center" valign="middle"  rowspan="2"  >0.610</td><td align="center" valign="middle"  rowspan="2"  >0.438</td></tr><tr><td align="center" valign="middle" >高HbA1C组(n = 33)</td><td align="center" valign="middle" >0.14 &#177; 0.10</td><td align="center" valign="middle" >0.14 &#177; 0.10</td><td align="center" valign="middle" >0.20 &#177; 0.11<sup>a</sup></td><td align="center" valign="middle" >0.18 &#177; 0.12</td><td align="center" valign="middle" >0.17 &#177; 0.11</td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub> = 41.548</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub><sub> </sub><sub>&#215;</sub><sub> </sub><sub>HbA1C</sub> = 2.160</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="2"  >P &lt; 0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >P = 0.122</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 不同HbA1c与时间对BCVA的影响</p><p>注：a表示与术前差异P &lt; 0.05；b表示与术后一周差异P &lt; 0.05；c表示与术后一月差异P &lt; 0.05；d表示与术后两月差异P &lt; 0.05；*表示与低糖化血红蛋白(HbA1C)差异P &lt; 0.05。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The influence of different HbA1c and time on CM</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后一周</th><th align="center" valign="middle" >术后一月</th><th align="center" valign="middle" >术后两月</th><th align="center" valign="middle" >术后三月</th><th align="center" valign="middle" >F<sub>HbA1C</sub></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >低HbA1C组(n = 35)</td><td align="center" valign="middle" >412.97 &#177; 115.95</td><td align="center" valign="middle" >384.46 &#177; 108.34</td><td align="center" valign="middle" >330.37 &#177; 54.78<sup>a </sup></td><td align="center" valign="middle" >336.66 &#177; 51.84<sup>a </sup></td><td align="center" valign="middle" >357.74 &#177; 67.86</td><td align="center" valign="middle"  rowspan="2"  >2.287</td><td align="center" valign="middle"  rowspan="2"  >0.135</td></tr><tr><td align="center" valign="middle" >高HbA1C组(n = 33)</td><td align="center" valign="middle" >419.91 &#177; 97.20</td><td align="center" valign="middle" >413.58 &#177; 89.68</td><td align="center" valign="middle" >349.88 &#177; 81.83<sup>ab* </sup></td><td align="center" valign="middle" >370.42 &#177; 72.77<sup>a* </sup></td><td align="center" valign="middle" >408.79 &#177; 99.70<sup>c* </sup></td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub> = 33.306</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub><sub> </sub><sub>&#215;</sub><sub> </sub><sub>HbA1C</sub> = 2.263</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="2"  >P &lt; 0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >P = 0.109</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表2. 不同HbA1c与时间对CMT的影响</p><p>注：a表示与术前差异P &lt; 0.05；b表示与术后一周差异P &lt; 0.05；c表示与术后一月差异P &lt; 0.05；d表示与术后两月差异P &lt; 0.05；*表示与低糖化血红蛋白(HbA1C)差异P &lt; 0.05。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The effect of different HbA1c and time on macular volum</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后一周</th><th align="center" valign="middle" >术后一月</th><th align="center" valign="middle" >术后两月</th><th align="center" valign="middle" >术后三月</th><th align="center" valign="middle" >F<sub>HbA1C</sub></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >低HbA1C组(n = 35)</td><td align="center" valign="middle" >12.12 &#177; 2.71</td><td align="center" valign="middle" >11.58 &#177; 2.74</td><td align="center" valign="middle" >9.85 &#177; 1.60<sup>ab </sup></td><td align="center" valign="middle" >9.95 &#177; 1.70<sup>ab </sup></td><td align="center" valign="middle" >10.16 &#177; 1.90<sup>a </sup></td><td align="center" valign="middle"  rowspan="2"  >2.146</td><td align="center" valign="middle"  rowspan="2"  >0.148</td></tr><tr><td align="center" valign="middle" >高HbA1C组(n = 33)</td><td align="center" valign="middle" >12.21 &#177; 2.68</td><td align="center" valign="middle" >12.16 &#177; 2.62</td><td align="center" valign="middle" >10.14 &#177; 2.09<sup>ab </sup></td><td align="center" valign="middle" >10.73 &#177; 2.24<sup>ab </sup></td><td align="center" valign="middle" >11.92 &#177; 2.65<sup>c* </sup></td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub> = 30.907</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub><sub> </sub><sub>&#215;</sub><sub> </sub><sub>HbA1C</sub> = 3.733</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="2"  >P &lt; 0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >P = 0.028</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 不同HbA1c与时间对黄斑容积的影响</p><p>注：a表示与术前差异P &lt; 0.05；b表示与术后一周差异P &lt; 0.05；c表示与术后一月差异P &lt; 0.05；d表示与术后两月差异P &lt; 0.05；*表示与低糖化血红蛋白(HbA1C)差异P &lt; 0.05。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Effect of different HbA1c and time on macular central visual acuit</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >术前</th><th align="center" valign="middle" >术后一周</th><th align="center" valign="middle" >术后一月</th><th align="center" valign="middle" >术后两月</th><th align="center" valign="middle" >术后三月</th><th align="center" valign="middle" >F<sub>HbA1C</sub></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >低HbA1C组(n = 35)</td><td align="center" valign="middle" >16.48 &#177; 4.20</td><td align="center" valign="middle" >17.10 &#177; 4.30</td><td align="center" valign="middle" >19.82 &#177; 3.83<sup>a </sup></td><td align="center" valign="middle" >19.09 &#177; 4.05</td><td align="center" valign="middle" >18.86 &#177; 4.18</td><td align="center" valign="middle"  rowspan="2"  >2.048</td><td align="center" valign="middle"  rowspan="2"  >0.157</td></tr><tr><td align="center" valign="middle" >高HbA1C组(n = 33)</td><td align="center" valign="middle" >16.62 &#177; 3.75</td><td align="center" valign="middle" >16.55 &#177; 3.75</td><td align="center" valign="middle" >18.09 &#177; 3.62</td><td align="center" valign="middle" >17.82 &#177; 4.00</td><td align="center" valign="middle" >16.04 &#177; 3.47<sup>* </sup></td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub> = 22.659</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >F<sub>时间</sub><sub> </sub><sub>&#215;</sub><sub> </sub><sub>HbA1C</sub> = 6.839</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle"  colspan="2"  >P &lt; 0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle"  colspan="2"  >P &lt; 0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 不同HbA1c与时间对黄斑中心视敏度的影响</p><p>注：a表示与术前差异P &lt; 0.05；b表示与术后一周差异P &lt; 0.05；c表示与术后一月差异P &lt; 0.05；d表示与术后两月差异P &lt; 0.05；*表示与低糖化血红蛋白(HbA1C)差异P &lt; 0.05。</p><p>变，黄斑区出现细胞外液的聚集，从而形成黄斑水肿 [<xref ref-type="bibr" rid="hanspub.27034-ref5">5</xref>] 。对黄斑水肿的治疗既要考虑到疗效，更要考虑到黄斑区的安全性，将医源性损伤降到最低。577 nm波长到达及局限作用于RPE细胞层，适当能量的微脉冲激光对RPE细胞具有高度的选择性，其照射眼底后所产生的能量会局限在此层细胞中，激光功率设计小、时间短、不产生可见光斑，很少向外传导，在造成RPE细胞光损伤后，邻近的RPE细胞会逐渐增生迁移来修补病损区，所以病变区会在短时间内恢复血–视网膜外屏障功能 [<xref ref-type="bibr" rid="hanspub.27034-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.27034-ref7">7</xref>] ，577 nm黄色激光具有在色素上皮层更佳的吸收和转换效果、对氧合血红蛋白及黑色素的高吸收率、对黄斑区叶黄素的极少吸收及光散射少等特点，这就保障了黄斑区激光治疗的最大安全性。因此577 nm激光阈下微脉冲治疗成为黄斑区首选的、最理想的激光治疗选择。然而临床实践中577 nm微脉冲的激光对黄斑水肿的治疗可以有效的缩短病程，但是会有一定的复发，也有部分患者对其治疗不敏感导致效果不佳 [<xref ref-type="bibr" rid="hanspub.27034-ref8">8</xref>] 。</p><p>本实验中577 nm激光治疗后两组黄斑水肿都有肯定的疗效，治疗后3 mo内眼底检查均未见任何激光光凝瘢痕，未见任何RPE色素脱失或增殖改变，其治疗是安全有效的。尤其是术后1月，黄斑中心厚度，黄斑容积都有明显的减少，以及黄斑中央微视野都有良好的改善，但是在高糖化组，术后三月有不同程度的黄斑水肿的复发。而低HbAlc组则维持了更长时间的治疗效果，黄斑中心厚度，黄斑容积，黄斑中心视敏度都较高HbAlc组有显著差异。提示HbAlc的良好控制能够更长时间地维持微脉冲激光的治疗效果。血糖的检测反映了瞬时的血糖水平，可受饮食、休息、心情、应激等情况的影响，而HbAlc可反映患者长期血糖控制情况，消除血糖波动对病情控制观察的影响。HbAlc已广泛应用于糖尿病的临床诊断中，并成为国际公认的评价长期血糖控制情况的“金指标” [<xref ref-type="bibr" rid="hanspub.27034-ref9">9</xref>] ，用来评价糖尿病慢性并发症的发生、发展情况。近年来，国内外学者对HbAlc与视网膜厚度的关系保持较高的关注度。有研究发现HbAlc是黄斑水肿的危险因素 [<xref ref-type="bibr" rid="hanspub.27034-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.27034-ref11">11</xref>] 。另有一项研究也发现糖尿病患者HbAlc值在8%或以上的情况下，通过OCT测量所得的黄斑区视网膜厚度出现增加，且严格的血糖控制能降低糖尿病患者黄斑病变的进程 [<xref ref-type="bibr" rid="hanspub.27034-ref12">12</xref>] 。本实验结果显示高糖化组同低糖化组，激光治疗后一月，两月黄斑中央厚度，黄斑容积都较治疗前有明显差异，但是在高糖化组黄斑水肿于三个月时再次出现，而低HbAlc组显示治疗效果维持了更长的时间，显示出严格的HbAlc控制能够使577 nm微脉冲治疗维持更长的时间和更好的效果。</p><p>提示严格的HbAlc控制不仅可以降低黄斑病变的进程，同样可以减少黄斑水肿激光治疗效果的波动，巩固和延长577 nm微脉冲激光对黄斑水肿DME临床疗效。</p></sec><sec id="s7"><title>基金项目</title><p>新疆生产建设兵团科技项目(项目编号2015AD029)。</p></sec><sec id="s8"><title>文章引用</title><p>张奕霞,练海东,丁剑锋,李 娜. 糖化血红蛋白对577 nm阈下微脉冲激光治疗糖尿病黄斑水肿的影响Effect of Glycosylated Hemoglobin on 577 nm Subthreshold Micro Pulse Laser in Treatment of Diabetic Macular Edema[J]. 眼科学, 2018, 07(03): 143-148. https://doi.org/10.12677/HJO.2018.73022</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.27034-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Regnier, S., Alsop, J., Wright, J., et al. (2016) Review and Comparison of Methodologies for Indirect Comparison of Clinical Trial Results: An Illustration with Ranibizumab and Aflibercep. Expert Review of Pharmacoeconomics &amp; Outcomes Research, 5, 345-347. https://doi.org/10.1586/14737167.2016.1165609</mixed-citation></ref><ref id="hanspub.27034-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">徐斌, 戴奕娟, 梁丽, 等. 传统格栅样激光与577 nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J]. 眼科新进展, 2014, 34(2): 181-183.</mixed-citation></ref><ref id="hanspub.27034-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Burak, T. and Tanyildizi, R. (2013) The Frequency of the Nonresponsiveness to Intravitreal Injection of the Anti-Vascular Endothelial Growth Factor Agent in Neovascular Age Related Macular Degeneration.  International Journal of Ophthalmic Pathology, 2, 2324-2326.</mixed-citation></ref><ref id="hanspub.27034-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chong, L.P., Soriano, D. and Ramos, A.R. (1996) Sublethal Laser Damage to the Retinal Pigment Epithelium by Micro-Pulse Diode Laser in Primate Eye. Investigative Ophthal-mology &amp; Visual Science, 37, 5694.</mixed-citation></ref><ref id="hanspub.27034-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Bhagat, N., Grigorian, R.A., Tutela, A., et al. (2009) Diabetic Macular Edema: Pathogenesis and Treatment. Survey of Ophthalmology, 54, 1-32. https://doi.org/10.1016/j.survophthal.2008.10.001</mixed-citation></ref><ref id="hanspub.27034-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Roider, J., Hillenkamp, F., Flotte, T. and Birngruber, R. (1993) Microphotocoagulation: Selective Effects in Biological Tissue Using Repetitive Short Laser Pulses. Proceedings of the National Academy of Sciences of the United States of America, 90, 8643-8647. https://doi.org/10.1073/pnas.90.18.8643</mixed-citation></ref><ref id="hanspub.27034-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Roider, J., Brinkmann, R., Wirbelauer, C., Laqua, H. and Birngruber, R. (1999) Retinal Sparing by Selective Retinal Pigment Epithelial Photocoagulation. Archives of Ophthalmology, 117, 1028-1034.  
https://doi.org/10.1001/archopht.117.8.1028</mixed-citation></ref><ref id="hanspub.27034-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">丁国鹏, 丁国龙, 雷姝, 等. 康柏西普联合577 nm微脉冲激光治疗糖尿病视性黄斑水肿临床观察[J]. 国际眼科杂志, 2015, 11(8): 1942-1944.</mixed-citation></ref><ref id="hanspub.27034-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Listed, N. (1991) Standards of Medical Care for Patients with Diabetes Mellitus. American Diabetes Association. Connecticut Medicine, 55, 630-633.</mixed-citation></ref><ref id="hanspub.27034-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ahmadpour-Baghdadabad, M., Manaviat, M. and Shojaoddiny Ardekani, A. (2013) Optical Coherence Tomography in Diabetic Macular Edema: Patterns and Related Risk Factors. Nepalese Journal of Ophthalmology, 5, 190-194.  
https://doi.org/10.3126/nepjoph.v5i2.8727</mixed-citation></ref><ref id="hanspub.27034-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Do, D.V., Shah, S.M., Sung, J.U., et al. (2005) Pesistent Diabetic Macular Edema Is Associated with Elevated Hemoglobin A1c. American Journal of Ophthalmology, 139, 620-623. https://doi.org/10.1016/j.ajo.2004.10.063</mixed-citation></ref><ref id="hanspub.27034-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Turgut, B., Gul, F.C., Iihan, N., et al. (2010) Comparison of Serum Glycosylated Hemoglobin Levels in Patients with Diabetic Cystoid Macular Edema with and without Serous Macular Detachment. Indian Journal of Ophthalmology, 58, 381-384. https://doi.org/10.4103/0301-4738.67044</mixed-citation></ref></ref-list></back></article>